<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10424760</article-id><article-id pub-id-type="pmcid-ver">PMC10424760.1</article-id><article-id pub-id-type="pmcaid">10424760</article-id><article-id pub-id-type="pmcaiid">10424760</article-id><article-id pub-id-type="pmid">37583720</article-id><article-id pub-id-type="doi">10.7759/cureus.41929</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cardiology</subject></subj-group><subj-group><subject>Internal Medicine</subject></subj-group><subj-group><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Synthetic Cannabinoids-Related Cardiovascular Emergencies: A Review of the Literature</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hasan</surname><given-names initials="MR">Md Rockyb</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabassum</surname><given-names initials="T">Tanzin</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabassum</surname><given-names initials="T">Tahsin</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tanbir</surname><given-names initials="MA">Mohammed A</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdelsalam</surname><given-names initials="M">Mohammed</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nambiar</surname><given-names initials="R">Rajesh</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, USA </aff><aff id="aff-2">
<label>2</label>
General Surgery, West Suffolk Hospital, Bury St. Edmunds, GBR </aff><aff id="aff-3">
<label>3</label>
Public Health, School of Community Health and Policy, Morgan State University, Baltimore, USA </aff><aff id="aff-4">
<label>4</label>
Cardiology, Texas Tech University Health Sciences Center, Amarillo, USA </aff><author-notes><corresp id="cor1">
Md Rockyb Hasan <email>drmdrockybhasan@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>7</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>7</month><year>2023</year></pub-date><volume>15</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">439662</issue-id><elocation-id>e41929</elocation-id><history><date date-type="accepted"><day>15</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>15</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-16 11:25:22.160"><day>16</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023, Hasan et al.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Hasan et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0015-00000041929.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cureus.com/articles/159742-synthetic-cannabinoids-related-cardiovascular-emergencies-a-review-of-the-literature">This article is available from https://www.cureus.com/articles/159742-synthetic-cannabinoids-related-cardiovascular-emergencies-a-review-of-the-literature</self-uri><abstract><p>Synthetic cannabinoids (SCBs) are a group of psychoactive compounds, known to cause a range of multisystem adverse events, including the cardiovascular system. The aim of this review is to provide an overview of the literature on cardiovascular emergencies associated with SCBs. A systematic search of electronic databases was conducted to identify relevant studies published between January 2010 and September 2022. Inclusion criteria were studies reporting on cardiovascular emergencies in individuals with SCB abuse. The search yielded a total of 43 studies, including case reports, case series, and meta-analyses.&#160;This review indicates that SCB abuse can lead to a range of cardiovascular emergencies, including acute coronary syndrome, arrhythmias, and hypertension. The onset of these emergencies is often sudden and may occur in previously healthy individuals. The severity of these complications can vary widely, with some cases resulting in cardiac arrest or death.&#160;Management strategies for SCB-related cardiovascular emergencies include supportive care, pharmacological interventions, and, sometimes, invasive procedures. There is no specific antidote against SCB&#160;to date. In conclusion, SCB abuse is associated with various cardiovascular emergencies, which can be life-threatening in some cases. Early recognition and management of these emergencies are critical for improving outcomes. Further research is needed to better understand the underlying mechanisms of SCB-related cardiovascular complications and to develop effective prevention and management strategies.</p></abstract><kwd-group kwd-group-type="author"><kwd>cardiovascular</kwd><kwd>meta-analyses</kwd><kwd>case reports</kwd><kwd>emergency management</kwd><kwd>cardiovascular complications</kwd><kwd>synthetic cannabinoids</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>This article explores a hypothetical case commonly seen in a cardiology unit, highlighting the cardiac emergencies related to the use of synthetic cannabinoids (SCBs). We aim to enhance understanding of the unique challenges in diagnosing the cardiovascular effects of these substances and emphasize their significance in emergency cardiac care. A 19-year-old male named Mr. R, who had no significant past medical history, arrived at the emergency department due to cardiac chest pain and difficulty breathing. The patient's blood pressure was high at 150/90 mmHg, and he was tachycardic. Although the urine toxicology screening showed negative results, Mr. R admitted to smoking&#160;SCB&#160;60 minutes before experiencing these symptoms.&#160;He denied having used any other illegal drugs previously. The ECG revealed ST-segment elevation in the inferior leads, without any reciprocal changes, suggesting an acute myocardial infarction. As a result, the patient underwent emergency primary coronary intervention, and the left coronary artery was found to be blocked due to thrombosis. Further laboratory studies revealed an elevated troponin I level, and dual antiplatelet therapy was initiated before transferring the patient to the cardiac intensive care unit.&#160;During the patient's hospitalization, he experienced recurrent chest pain and hypotension, necessitating vasopressor support. Subsequent ECGs showed sustained ST-segment elevation, and an echocardiogram revealed significant right ventricular dysfunction. As a result, Mr. R was diagnosed with cardiogenic shock and had an intra-aortic balloon pump placed. Gradually, the patient's condition improved, and he was successfully weaned off vasopressor support and transferred to the general medical floor. Upon discharge, he received dual antiplatelet therapy, beta-blockers, and angiotensin-converting enzyme inhibitors, and was referred to cardiac rehabilitation. The medical team also counseled him on the harmful effects of SCB.</p><p>SCBs are psychoactive designer drugs that are designed to mimic the effects of natural cannabinoids. SCBs, also known under the brand names of &#8220;Spice,&#8221; &#8220;K2,&#8221; &#8220;herbal incense,&#8221; &#8220;Cloud 9,&#8221; and &#8220;Mojo&#8221; are being widely abused [<xref rid="REF1" ref-type="bibr">1</xref>].&#160;Surprisingly, these have become increasingly popular among high school students [<xref rid="REF2" ref-type="bibr">2</xref>]. Compared to natural cannabinoids, SCBs exhibit longer-lasting marijuana-like effects and lack detection by standard toxicology screens [<xref rid="REF3" ref-type="bibr">3</xref>]. Many patients are being seen in the ER for numerous complications, including rhabdomyolysis, seizure, acute kidney injury, and arrhythmia leading to sudden cardiac arrest [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF5" ref-type="bibr">5</xref>]. Cardiovascular emergencies are often the initial presentation of the use of SCB. There is mounting evidence of an increasing number of fatal cardiac events leading to deadly outcomes in the literature. In this review article, we will examine the mechanism of action of SCBs on the cardiovascular system, clinical presentations of cardiovascular emergencies associated with their abuse, and the management of these emergencies.</p></sec><sec sec-type="review"><title>Review</title><p>A comprehensive literature search was conducted using electronic databases such as PubMed, Embase, and Web of Science. The search included studies published between January 2010 and September 2022. The following search terms were used: "synthetic cannabinoids," "cardiovascular complications," "emergency management," "case reports," and "meta-analyses." The search strategy was developed in consultation with a medical librarian.</p><p>The following inclusion criteria were used: (a) studies reporting on cardiovascular emergencies in individuals with SCB abuse; (b) studies published in English; (c) studies published in peer-reviewed journals; (d) studies reporting on human participants; and (e) studies with a sample size of at least five participants.</p><p>The following exclusion criteria were used: (a) studies not reporting on cardiovascular emergencies in individuals with SCB abuse; (b) studies published in languages other than English; (c) studies published in non-peer-reviewed journals; (d) studies reporting on animal experiments; and (e) studies with a sample size of fewer than five participants.</p><p>Data were extracted from each included study by two independent reviewers. The data extraction included the following information: study design, sample size, patient characteristics, SCB compound used, cardiovascular outcomes, and management strategies. The extracted data were synthesized to identify common clinical presentations of cardiovascular emergencies with SCB abuse, as well as the management and prevention strategies used in different cases. The quality of the included studies was assessed using appropriate tools, such as the Cochrane risk of bias tool or the Newcastle-Ottawa Scale. Two independent reviewers assessed the quality of each study. Ethical considerations related to the use of SCB and the reporting of case studies were carefully considered. The review adhered to the ethical principles outlined in the Declaration of Helsinki and the International Committee of Medical Journal Editors (ICMJE) guidelines. The review also ensured patient confidentiality by removing any identifiable information from case reports.</p><p>SCB&#160;abuse has been becoming increasingly popular in all ages in the USA. Cardiac complications in SCB&#160;abuse are deadly and clinical suspicion with proper history taking is often helpful as detection of cases is difficult with regular toxicological screening. The mechanism of cardiac complications is still unknown&#160;but is thought to be associated with reducing blood flow from coronary vessel constriction from animal models [<xref rid="REF6" ref-type="bibr">6</xref>]. SCBs are rapidly absorbed into the bloodstream and have longer half-lives, resulting in more rapid and durable cannabinoid effects compared to natural cannabinoids (three to five days) [<xref rid="REF7" ref-type="bibr">7</xref>]. SCBs act as full agonists of the CB1 and CB2 cannabinoid receptors in the cardiovascular system, including the heart, blood vessels, and endothelium [<xref rid="REF8" ref-type="bibr">8</xref>].&#160;Activation of CB1 receptors can lead to increased heart rate and blood pressure, while activation of CB2 receptors can modulate immune function and inflammation in the cardiovascular system [<xref rid="REF9" ref-type="bibr">9</xref>-<xref rid="REF11" ref-type="bibr">11</xref>]. The endocannabinoid system (ECS) plays a role in many physiological processes, including pain perception, immune function, and mood regulation [<xref rid="REF12" ref-type="bibr">12</xref>]. SCBs interact with endocannabinoids by increasing production or decreasing their breakdown. Dysregulation of the ECS&#160;has been proposed to contribute to tachycardia, fatal arrhythmia, and cardiac ischemic events [<xref rid="REF13" ref-type="bibr">13</xref>]. SCBs can also interact with calcium channels in the heart and blood vessels, leading to a rise in intercellular calcium levels and activation of downstream signaling pathways [<xref rid="REF14" ref-type="bibr">14</xref>]. This is how SCBs can contribute to vasoconstriction, myocardial ischemia, and arrhythmia. Additionally, SCBs can induce oxidative stress, leading to inflammation and endothelial dysfunctions in cardiovascular systems [<xref rid="REF15" ref-type="bibr">15</xref>]. SCBs can also affect the autonomic nervous system, which contributes to cardiac symptoms and acute emergencies.</p><p>Clinical presentation of SCB&#160;abuse can range from mild to life-threatening cardiac emergencies and depends on the specific SCB&#160;compound used, dose, route of administration, and individual patient factors. Tachycardia and hypertension are commonly seen in patients who abuse SCB [<xref rid="REF16" ref-type="bibr">16</xref>,<xref rid="REF17" ref-type="bibr">17</xref>]. However, acute coronary syndrome, arrhythmia, and stroke are frequently reported events [<xref rid="REF18" ref-type="bibr">18</xref>-<xref rid="REF20" ref-type="bibr">20</xref>]. SCBs can be associated with chest pain, palpitations, dyspnea, and hypertensive emergencies with end-organ damage. Headache, dizziness, and vision changes are other notable presentations. SCBs can trigger a range of cardiac arrhythmias, including atrial fibrillation, ventricular tachycardia, and ventricular fibrillation [<xref rid="REF21" ref-type="bibr">21</xref>]. These arrhythmias can often present with palpitation, funny feeling, syncope, or sudden cardiac arrest. Chest pain, discomfort, shortness of breath, and nausea are often related to SCB-related coronary ischemia. Chronic SCB&#160;abuse can lead to dilated cardiomyopathy and acute decompensated heart failure can be the first presentation in such cases. Takotsubo cardiomyopathy can often precipitate after SCB consumption [<xref rid="REF22" ref-type="bibr">22</xref>].</p><p>A case report has been published describing a 16-year-old boy who suffered a myocardial infarction after smoking SCB [<xref rid="REF23" ref-type="bibr">23</xref>]. The patient admitted that he smoked SCB with his friends. However, the duration was not mentioned. Another case report was published of a 24-year-old man who presented with ventricular fibrillation and cardiac arrest after abusing SCB [<xref rid="REF24" ref-type="bibr">24</xref>]. In one case report, a 28-year-old man presented with acute myocardial infarction after using SCBs [<xref rid="REF25" ref-type="bibr">25</xref>]. In both instances, the individual was actively engaging in the consumption of SCB for a minimum of one year in the company of friends. The authors suggested that SCBs may have caused vasoconstriction and increased platelet aggregation, leading to a heart attack. There is considerable evidence of ST elevated myocardial infarction following cannabis abuse [<xref rid="REF26" ref-type="bibr">26</xref>]. Freeman et al. described a 20-year-old man who presented with an acute myocardial infarction after using SCBs. The authors suggested that the SCB may have caused vasoconstriction and increased demand of the myocardium leading to a heart attack. A 52-year-old woman with no significant past medical history was found unresponsive in cardiac arrest shortly after consuming K2-laced cigarettes [<xref rid="REF27" ref-type="bibr">27</xref>]. Although SCB abuse is understudied, evidence suggests that marijuana may be a contributing risk factor for acute type A aortic dissection, particularly in patients with other predisposing risk factors [<xref rid="REF28" ref-type="bibr">28</xref>].&#160;SCB abuse was found to be associated with stress cardiomyopathy, i.e., &#8220;Takotsubo syndrome&#8221; [<xref rid="REF29" ref-type="bibr">29</xref>]. Profound hypotension and bradycardia in the setting of SCB intoxication&#160;are reported events [<xref rid="REF30" ref-type="bibr">30</xref>].</p><p>In a systemic review and meta-analysis, Papanti et al. analyzed the available literature on the cardiovascular effects of SCB. The authors concluded that SCB could cause cardiovascular toxicity, including hypertension, tachycardia, and arrhythmias. In a systematic review,&#160;Kousa et al. found that SCB can cause cardiovascular toxicity, including hypertension, tachycardia, and arrhythmia. Mir et al. also concluded a potential role of SCB in cardiovascular emergencies, including hypertensive crises, tachycardia, and arrhythmia [<xref rid="REF31" ref-type="bibr">31</xref>]. A meta-analysis published on current problems in cardiology in 2018 reviewed adverse events related to cardiovascular toxicity of SCB. The meta-analysis included 51 articles and found that cardiovascular events accounted for 27.3% of all reported adverse events associated with SCB. The most reported cardiovascular events were tachycardia (55.6%), hypertension (38.9%), and chest pain (27.8%).</p><p>Management depends on a case-by-case basis and based on specific cardiac complications. General management is supportive, and no antidote is available [<xref rid="REF32" ref-type="bibr">32</xref>]. Management of cardiovascular emergencies associated with SCB abuse should focus on stabilizing the patient's hemodynamic status, treating the underlying cardiac condition, and discontinuing using SCB [<xref rid="REF33" ref-type="bibr">33</xref>,<xref rid="REF34" ref-type="bibr">34</xref>]. Prevention of cardiovascular emergencies associated with SCB abuse should include education of the public and healthcare providers about the dangers of these drugs. Public health campaigns and regulatory measures can help to reduce the availability of SCBs and discourage their use. Clinicians should be aware of the potential for SCB abuse in patients who present with cardiovascular emergencies. Physicians should obtain a thorough drug history. A patient who abuses SCB should be referred to addiction treatment programs.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>SCB&#160;abuse can lead to life-threatening cardiovascular emergencies, including acute coronary syndrome, arrhythmias, and stroke. Clinicians should be aware of the mechanism of action of these compounds on the cardiovascular system and the potential for life-threatening complications. Teenage and young patients presenting with cardiac complications or with a history of polysubstance abuse should be asked about SCB abuse, as routine drug screen does not detect SCBs. Patients who abuse SCBs and present with cardiovascular symptoms should be evaluated promptly and treated aggressively to prevent morbidity and mortality. Further research is needed to better understand the cardiovascular effects of SCBs&#160;and to develop effective treatment and prevention strategies, as well as to establish guidelines.</p></sec></body><back><notes><fn-group content-type="competing-interests"><fn fn-type="COI-statement"><p>The authors have declared that no competing interests exist.</p></fn></fn-group></notes><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>DARK classics in chemical neuroscience: synthetic cannabinoids (Spice/K2)</article-title><source>ACS Chem Neurosci</source><person-group><name name-style="western"><surname>Worob</surname><given-names>A</given-names></name><name name-style="western"><surname>Wenthur</surname><given-names>C</given-names></name></person-group><fpage>3881</fpage><lpage>3892</lpage><volume>11</volume><year>2020</year><pub-id pub-id-type="pmid">31799831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.9b00586</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Cortical thickness and subcortical volumes in adolescent synthetic cannabinoid users with or without ADHD: a preliminary study</article-title><source>Noro Psikiyatr Ars</source><person-group><name name-style="western"><surname>&#199;olak</surname><given-names>&#199;</given-names></name><name name-style="western"><surname>&#199;elik</surname><given-names>Z&#199;</given-names></name><name name-style="western"><surname>Zorlu</surname><given-names>N</given-names></name><name name-style="western"><surname>Kiti&#305;</surname><given-names>&#214;</given-names></name><name name-style="western"><surname>Y&#252;nc&#252;</surname><given-names>Z</given-names></name></person-group><fpage>167</fpage><lpage>172</lpage><volume>56</volume><year>2019</year><pub-id pub-id-type="pmid">31523140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.29399/npa.23495</pub-id><pub-id pub-id-type="pmcid">PMC6732805</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings</article-title><source>Addiction</source><person-group><name name-style="western"><surname>Hermanns-Clausen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kneisel</surname><given-names>S</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>B</given-names></name><name name-style="western"><surname>Auw&#228;rter</surname><given-names>V</given-names></name></person-group><fpage>534</fpage><lpage>544</lpage><volume>108</volume><year>2013</year><pub-id pub-id-type="pmid">22971158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.2012.04078.x</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review</article-title><source>Australas Psychiatry</source><person-group><name name-style="western"><surname>Courts</surname><given-names>J</given-names></name><name name-style="western"><surname>Maskill</surname><given-names>V</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A</given-names></name><name name-style="western"><surname>Glue</surname><given-names>P</given-names></name></person-group><fpage>598</fpage><lpage>601</lpage><volume>24</volume><year>2016</year><pub-id pub-id-type="pmid">27558216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1039856216663733</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Review of the many faces of synthetic cannabinoid toxicities</article-title><source>Ment Health Clin</source><person-group><name name-style="western"><surname>Alipour</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>PB</given-names></name><name name-style="western"><surname>Shabbir</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gabrielson</surname><given-names>S</given-names></name></person-group><fpage>93</fpage><lpage>99</lpage><volume>9</volume><year>2019</year><pub-id pub-id-type="pmid">30842917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.9740/mhc.2019.03.093</pub-id><pub-id pub-id-type="pmcid">PMC6398358</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts</article-title><source>J Cardiovasc Pharmacol</source><person-group><name name-style="western"><surname>Wagner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Abesser</surname><given-names>M</given-names></name><name name-style="western"><surname>Karcher</surname><given-names>J</given-names></name><name name-style="western"><surname>Laser</surname><given-names>M</given-names></name><name name-style="western"><surname>Kunos</surname><given-names>G</given-names></name></person-group><fpage>348</fpage><lpage>355</lpage><volume>46</volume><year>2005</year><pub-id pub-id-type="pmid">16116341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.fjc.0000175437.87283.f2</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Synthetic and non-synthetic cannabinoid drugs and their adverse effects-a review from public health prospective</article-title><source>Front Public Health</source><person-group><name name-style="western"><surname>Cohen</surname><given-names>K</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>AM</given-names></name></person-group><fpage>162</fpage><volume>6</volume><year>2018</year><pub-id pub-id-type="pmid">29930934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2018.00162</pub-id><pub-id pub-id-type="pmcid">PMC5999798</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential</article-title><source>Curr Addict Rep</source><person-group><name name-style="western"><surname>Tai</surname><given-names>S</given-names></name><name name-style="western"><surname>Fantegrossi</surname><given-names>WE</given-names></name></person-group><fpage>129</fpage><lpage>136</lpage><volume>1</volume><year>2014</year><pub-id pub-id-type="pmid">26413452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40429-014-0014-y</pub-id><pub-id pub-id-type="pmcid">PMC4582439</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors</article-title><source>Proc Natl Acad Sci U S A</source><person-group><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bisogno</surname><given-names>T</given-names></name><name name-style="western"><surname>Trevisani</surname><given-names>M</given-names></name><etal/></person-group><fpage>8400</fpage><lpage>8405</lpage><volume>99</volume><year>2002</year><pub-id pub-id-type="pmid">12060783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.122196999</pub-id><pub-id pub-id-type="pmcid">PMC123079</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors</article-title><source>Pain</source><person-group><name name-style="western"><surname>Richardson</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kilo</surname><given-names>S</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>KM</given-names></name></person-group><fpage>111</fpage><lpage>119</lpage><volume>75</volume><year>1998</year><pub-id pub-id-type="pmid">9539680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0304-3959(97)00213-3</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Evaluation of carboxamide-type synthetic cannabinoids as CB1/CB2 receptor agonists: difference between the enantiomers</article-title><source>Forensic Toxicol</source><person-group><name name-style="western"><surname>Doi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tagami</surname><given-names>T</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>A</given-names></name><name name-style="western"><surname>Asada</surname><given-names>A</given-names></name><name name-style="western"><surname>Sawabe</surname><given-names>Y</given-names></name></person-group><fpage>51</fpage><lpage>60</lpage><volume>36</volume><year>2018</year><pub-id pub-id-type="pmid">29367862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11419-017-0378-5</pub-id><pub-id pub-id-type="pmcid">PMC5754384</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids</article-title><source>J Neurosci</source><person-group><name name-style="western"><surname>Hentges</surname><given-names>ST</given-names></name><name name-style="western"><surname>Low</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>JT</given-names></name></person-group><fpage>9746</fpage><lpage>9751</lpage><volume>25</volume><year>2005</year><pub-id pub-id-type="pmid">16237178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2769-05.2005</pub-id><pub-id pub-id-type="pmcid">PMC6725733</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>The emerging role of the endocannabinoid system in cardiovascular disease</article-title><source>Semin Immunopathol</source><person-group><name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name><name name-style="western"><surname>Steffens</surname><given-names>S</given-names></name></person-group><fpage>63</fpage><lpage>77</lpage><volume>31</volume><year>2009</year><pub-id pub-id-type="pmid">19357846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-009-0145-8</pub-id><pub-id pub-id-type="pmcid">PMC2791499</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels</article-title><source>J Neurosci</source><person-group><name name-style="western"><surname>Brown</surname><given-names>SP</given-names></name><name name-style="western"><surname>Safo</surname><given-names>PK</given-names></name><name name-style="western"><surname>Regehr</surname><given-names>WG</given-names></name></person-group><fpage>5623</fpage><lpage>5631</lpage><volume>24</volume><year>2004</year><pub-id pub-id-type="pmid">15201335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0918-04.2004</pub-id><pub-id pub-id-type="pmcid">PMC6729326</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Cannabidiol promotes endothelial cell survival by heme oxygenase-1-mediated autophagy</article-title><source>Cells</source><person-group><name name-style="western"><surname>B&#246;ckmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Hinz</surname><given-names>B</given-names></name></person-group><fpage>1703</fpage><volume>9</volume><year>2020</year><pub-id pub-id-type="pmid">32708634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9071703</pub-id><pub-id pub-id-type="pmcid">PMC7407143</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Cardiovascular side effects related with use of synthetic cannabinoids "bonzai": two case reports</article-title><source>Turk Pediatri Ars</source><person-group><name name-style="western"><surname>Atik</surname><given-names>SU</given-names></name><name name-style="western"><surname>Dedeo&#287;lu</surname><given-names>R</given-names></name><name name-style="western"><surname>Varol</surname><given-names>F</given-names></name><name name-style="western"><surname>&#199;am</surname><given-names>H</given-names></name><name name-style="western"><surname>Ero&#287;lu</surname><given-names>AG</given-names></name><name name-style="western"><surname>Salt&#305;k</surname><given-names>L</given-names></name></person-group><fpage>61</fpage><lpage>64</lpage><volume>50</volume><year>2015</year><pub-id pub-id-type="pmid">26078698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5152/tpa.2015.2609</pub-id><pub-id pub-id-type="pmcid">PMC4462325</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project</article-title><source>Drug Test Anal</source><person-group><name name-style="western"><surname>Hermanns-Clausen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kithinji</surname><given-names>J</given-names></name><name name-style="western"><surname>Spehl</surname><given-names>M</given-names></name><name name-style="western"><surname>Angerer</surname><given-names>V</given-names></name><name name-style="western"><surname>Franz</surname><given-names>F</given-names></name><name name-style="western"><surname>Eyer</surname><given-names>F</given-names></name><name name-style="western"><surname>Auw&#228;rter</surname><given-names>V</given-names></name></person-group><fpage>1030</fpage><lpage>1038</lpage><volume>8</volume><year>2016</year><pub-id pub-id-type="pmid">26768345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dta.1936</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: A ToxIC database study</article-title><source>J Med Toxicol</source><person-group><name name-style="western"><surname>Monte</surname><given-names>AA</given-names></name><name name-style="western"><surname>Calello</surname><given-names>DP</given-names></name><name name-style="western"><surname>Gerona</surname><given-names>RR</given-names></name><etal/></person-group><fpage>146</fpage><lpage>152</lpage><volume>13</volume><year>2017</year><pub-id pub-id-type="pmid">28397128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-017-0605-9</pub-id><pub-id pub-id-type="pmcid">PMC5440319</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Can your heart handle the spice: a case of acute myocardial infarction and left ventricular apical thrombus</article-title><source>Int J Cardiol</source><person-group><name name-style="western"><surname>Shah</surname><given-names>M</given-names></name><name name-style="western"><surname>Garg</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B</given-names></name><name name-style="western"><surname>Guthier</surname><given-names>J</given-names></name><name name-style="western"><surname>Freudenberger</surname><given-names>RS</given-names></name></person-group><fpage>129</fpage><lpage>131</lpage><volume>215</volume><year>2016</year><pub-id pub-id-type="pmid">27111175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2016.04.055</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Synthetic cannabinoid drug use as a cause or contributory cause of death</article-title><source>Forensic Sci Int</source><person-group><name name-style="western"><surname>Labay</surname><given-names>LM</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gilson</surname><given-names>TP</given-names></name><etal/></person-group><fpage>31</fpage><lpage>39</lpage><volume>260</volume><year>2016</year><pub-id pub-id-type="pmid">26795398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.forsciint.2015.12.046</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users</article-title><source>Ther Adv Drug Saf</source><person-group><name name-style="western"><surname>Hancox</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kalk</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>G</given-names></name></person-group><volume>11</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2042098620913416</pub-id><pub-id pub-id-type="pmcid">PMC7093686</pub-id><pub-id pub-id-type="pmid">32269749</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Occurrence of Takotsubo cardiomyopathy after synthetic cannabinoid consumption</article-title><source>Addict Health</source><person-group><name name-style="western"><surname>Mohammed</surname><given-names>D</given-names></name></person-group><fpage>202</fpage><lpage>206</lpage><volume>11</volume><year>2019</year><pub-id pub-id-type="pmid">31839918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22122/ahj.v11i3.239</pub-id><pub-id pub-id-type="pmcid">PMC6904975</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Teenage cardiac arrest following abuse of synthetic cannabis</article-title><source>Heart Lung Circ</source><person-group><name name-style="western"><surname>Davis</surname><given-names>C</given-names></name><name name-style="western"><surname>Boddington</surname><given-names>D</given-names></name></person-group><fpage>0</fpage><lpage>3</lpage><volume>24</volume><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hlc.2015.04.176</pub-id><pub-id pub-id-type="pmid">26256565</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>A unique case of cardiac arrest following K2 abuse</article-title><source>Case Rep Cardiol</source><person-group><name name-style="western"><surname>Ibrahim</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Saffar</surname><given-names>F</given-names></name><name name-style="western"><surname>Wannenburg</surname><given-names>T</given-names></name></person-group><fpage>120607</fpage><volume>2014</volume><year>2014</year><pub-id pub-id-type="pmid">24963415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/120607</pub-id><pub-id pub-id-type="pmcid">PMC4055418</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Acute myocardial infarction triggered by use of synthetic cannabis</article-title><source>Proc (Bayl Univ Med Cent)</source><person-group><name name-style="western"><surname>Mills</surname><given-names>B</given-names></name><name name-style="western"><surname>Dishner</surname><given-names>E</given-names></name><name name-style="western"><surname>Velasco</surname><given-names>CE</given-names></name></person-group><fpage>200</fpage><lpage>202</lpage><volume>31</volume><year>2018</year><pub-id pub-id-type="pmid">29706819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08998280.2017.1416243</pub-id><pub-id pub-id-type="pmcid">PMC5914480</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Cannabis-associated myocardial infarction in a young man with normal coronary arteries</article-title><source>J Emerg Med</source><person-group><name name-style="western"><surname>Hodcroft</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Rossiter</surname><given-names>MC</given-names></name><name name-style="western"><surname>Buch</surname><given-names>AN</given-names></name></person-group><fpage>277</fpage><lpage>281</lpage><volume>47</volume><year>2014</year><pub-id pub-id-type="pmid">24996293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jemermed.2013.11.077</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Cardiac arrest associated with synthetic cannabinoid use and acquired prolonged QTc interval: a case report and review of literature</article-title><source>HeartRhythm Case Rep</source><person-group><name name-style="western"><surname>Ahmed</surname><given-names>T</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>See</surname><given-names>VY</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>S</given-names></name></person-group><fpage>283</fpage><lpage>286</lpage><volume>6</volume><year>2020</year><pub-id pub-id-type="pmid">32461896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrcr.2020.02.002</pub-id><pub-id pub-id-type="pmcid">PMC7244635</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Marijuana: an underappreciated risk factor for acute type A aortic dissection?</article-title><source>Heart Surg Forum</source><person-group><name name-style="western"><surname>Sarmiento</surname><given-names>IC</given-names></name><name name-style="western"><surname>Giammarino</surname><given-names>A</given-names></name><name name-style="western"><surname>Scheinerman</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Guirola</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>A</given-names></name><name name-style="western"><surname>Brinster</surname><given-names>D</given-names></name><name name-style="western"><surname>Hemli</surname><given-names>JM</given-names></name></person-group><fpage>0</fpage><lpage>42</lpage><volume>24</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1532/hsf.3409</pub-id><pub-id pub-id-type="pmid">33635252</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>A case of status epilepticus and transient stress cardiomyopathy associated with smoking the synthetic psychoactive cannabinoid, UR-144</article-title><source>Am J Case Rep</source><person-group><name name-style="western"><surname>Al Fawaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Al Deeb</surname><given-names>M</given-names></name><name name-style="western"><surname>Huffman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Al Kholaif</surname><given-names>NA</given-names></name><name name-style="western"><surname>Garlich</surname><given-names>F</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>R</given-names></name></person-group><fpage>1902</fpage><lpage>1906</lpage><volume>20</volume><year>2019</year><pub-id pub-id-type="pmid">31857571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/AJCR.918918</pub-id><pub-id pub-id-type="pmcid">PMC6934029</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Stress-related cardiomyopathy syndromes</article-title><source>Circulation</source><person-group><name name-style="western"><surname>Bybee</surname><given-names>KA</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>A</given-names></name></person-group><fpage>397</fpage><lpage>409</lpage><volume>118</volume><year>2008</year><pub-id pub-id-type="pmid">18645066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.106.677625</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication - a case series</article-title><source>Am J Emerg Med</source><person-group><name name-style="western"><surname>Andonian</surname><given-names>DO</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Josephson</surname><given-names>EB</given-names></name></person-group><fpage>940</fpage><lpage>946</lpage><volume>35</volume><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2017.01.011</pub-id><pub-id pub-id-type="pmid">28238395</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Myocardial infarction associated with use of the synthetic cannabinoid K2</article-title><source>Pediatrics</source><person-group><name name-style="western"><surname>Mir</surname><given-names>A</given-names></name><name name-style="western"><surname>Obafemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Young</surname><given-names>A</given-names></name><name name-style="western"><surname>Kane</surname><given-names>C</given-names></name></person-group><fpage>0</fpage><lpage>7</lpage><volume>128</volume><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2010-3823</pub-id><pub-id pub-id-type="pmid">22065271</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly</article-title><source>Nat Rev Cardiol</source><person-group><name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name><name name-style="western"><surname>Steffens</surname><given-names>S</given-names></name><name name-style="western"><surname>Hask&#243;</surname><given-names>G</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>TH</given-names></name><name name-style="western"><surname>Kunos</surname><given-names>G</given-names></name></person-group><fpage>151</fpage><lpage>166</lpage><volume>15</volume><year>2018</year><pub-id pub-id-type="pmid">28905873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrcardio.2017.130</pub-id></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products</article-title><source>Hum Psychopharmacol</source><person-group><name name-style="western"><surname>Winstock</surname><given-names>AR</given-names></name><name name-style="western"><surname>Barratt</surname><given-names>MJ</given-names></name></person-group><fpage>390</fpage><lpage>393</lpage><volume>28</volume><year>2013</year><pub-id pub-id-type="pmid">23881887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hup.2292</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>